VOLT-02 is a water-soluble conjugate of progesterone and a neurosteroid which is under development by Levolta Pharmaceuticals (formerly Voltarra Pharmaceuticals) for the treatment of traumatic brain injury, gynecological disorders, and menstrual disorders.[1] As of March 2017, it is in phase II clinical trials for these indications.[1] The chemical structure of VOLT-02 does not appear to have been released yet.[1]

VOLT-02
Clinical data
Other namesProgesterone conjugate
Drug classProgestogen; Neurosteroid
Identifiers
CAS Number

See also

edit

References

edit
  1. ^ a b c "Progesterone conjugate - Levolta Pharmaceuticals - AdisInsight". adisinsight.springer.com.
edit